Epigenetics Market To Reach USD 7.9 Billion By 2032 Report By DataHorizzon Research
January 19, 2024 06:30 ET
|
DataHorizzon Research
Fort Collins, Colorado, Jan. 19, 2024 (GLOBE NEWSWIRE) -- The Epigenetics Market size was valued at USD 1.8 Billion in 2022 and is expected to reach a market size of USD 7.9 Billion by 2032 with a...
Epigenetics Diagnostics Market to 2028 - Key Market Drivers & Challenges
January 18, 2024 21:03 ET
|
Research and Markets
Dublin, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to ...
Global Metagenomics Market Analysis 2023-2027: Breakthrough Insights in Medical Treatment and Microbiome Research by Application, Technology, Product and User
January 16, 2024 11:18 ET
|
Research and Markets
Dublin, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User. With Executive and Consultant Guides. 2023...
Epigenetics Market Predicted to Garner USD 12.7 Billion By 2033, At CAGR 19.2% | Exclusive Report by Marketresearch.biz
January 16, 2024 03:58 ET
|
MarketResearch.biz
New York, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The epigenetics market was valued at USD 2.3 billion in 2023 with a significant growth and is projected to reach at USD 12.7 billion by 2033 with a CAGR...
Global Epigenetics Market Poised for Rapid Growth - Asia-Pacific Region to Witness Extensive Expansion by 2028
January 03, 2024 09:03 ET
|
Research and Markets
Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The "Global Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method...
Cancer Tumor Profiling Market Size Worth USD 32.72 Billion by 2032 | Emergen Research
December 11, 2023 08:15 ET
|
Emergen Research
Vancouver, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Cancer Tumor Profiling Market is expected to reach USD 32.72 Billion by 2032, according to a new report by Emergen Research. This market's growth is...
Epic Bio to Present at the Upcoming CRISPR2.0 Conference
November 21, 2023 12:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
FDA Grants Orphan Drug Designation to EPI-321, Epic Bio's Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
November 16, 2023 06:00 ET
|
Epic Bio
- Potential one-time therapy for the treatment of FSHD includes a novel non-cutting dCas protein delivered via a single AAV - - EPI-321 is the only therapy designed to target the epigenetic root...
Epic Bio to Participate in Upcoming Investor Conference
November 07, 2023 06:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
Epic Bio Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
October 26, 2023 11:09 ET
|
Epic Bio
Epic Bio presented new details on an in-house engineered suite of Cas molecules derived from CasMINI, the smallest Cas known to work in human cells.